30 completed, 22 unknown, 19 recruiting, 14 not yet recruiting. 113 Phase 2, 18 Phase 1, 4 Phase 3.
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 52 | 2026-12-01 | 2026-10-20 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-04 | 2026-10-30 |
| Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Colchicine 0.5 MG Oral Tablet, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria di Modena | 87 | 2026-10-01 | 2026-09-10 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| Perioperative Adebrelimab for Locally Advanced Cervical Cancer Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 35 | 2026-10-01 | 2026-09-10 |
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 33 | 2026-09-10 | 2026-09-09 |
| Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy Sacituzumab Tirumotecan - Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC) | Phase 2 | Not yet recruiting | Virginia Commonwealth University | 20 | 2026-08-31 | 2026-08-24 |
| Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma Finotonlimab, Nab-paclitaxel, carboplatin - Head & Neck Cancer | Phase 2 | Not yet recruiting | Tang-Du Hospital | 15 | 2026-08-23 | 2026-08-07 |
| Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI - Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 85 | 2026-08-01 | 2026-08-24 |
| Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell Carcinoma Intermittent Hypoxic Training (IHT), Standard Neoadjuvant Chemo-immunotherapy - Lung Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC) | Phase 2 | Not yet recruiting | zhang yi | 60 | 2026-06-01 | 2026-06-01 |
| Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma Vibecotamab Injection - Head & Neck Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tang-Du Hospital | 10 | 2026-04-23 | 2026-04-20 |
| Clinical Effects of Alpha-Lipoic Acid in Advanced NSCLC Alpha Lipoic Acid 600mg - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Ain Shams University | 60 | 2026-04-20 | 2026-05-08 |
| Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients Regorafenib (BAY 73-4506) - Carcinoma, Hepatocellular, Hepatic Insufficien | Phase 2 | Not yet recruiting | Ju Hyun Shim | 20 | 2026-03-15 | 2026-04-07 |
| Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer Short-Course Radiotherapy Combined with Chemotherapy and Immunotherapy - Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II | Phase 2 | Not yet recruiting | Beijing Friendship Hospital | 19 | 2026-03-01 | 2026-02-11 |
| NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection - Upper Tract Urothelial Carcinoma | Phase 2 | Not yet recruiting | Peking University Third Hospital | 40 | 2026-02-01 | 2026-02-17 |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer E-EDV-D682, EDV-GC, Gemcitabine - Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Engeneic Pty Limited | 144 | 2026-01-12 | 2026-02-27 |
| Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial chemotherapy plus cemiplimab, Cemiplimab - NSCLC (Non-small Cell Lung Cancer), Hyperprogression | Phase 2 | Not yet recruiting | Università Vita-Salute San Raffaele | 74 | 2026-01-01 | 2025-12-10 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
Showing 20 of 113. Sign in to see all of them.
Pathologic Complete Response (48) · Breast Neoplasms (18) · Leukemia, Myeloid, Acute (9) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasm Metastasis (6) · Neoplasms (6) · Recurrence (6) · HIV Infections (5) · Head and Neck Neoplasms (5) · Ovarian Neoplasms (5) · Glioma (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Rectal Neoplasms (4)
Disease Attributes (113) · Pathologic Processes (113) · Pathological Conditions, Signs and Symptoms (112) · Neoplasms (76) · Neoplasms by Site (56) · Neoplasms by Histologic Type (40) · Hemic and Lymphatic Diseases (21) · Immune System Diseases (20) · Skin Diseases (20) · Skin and Connective Tissue Diseases (20) · Hematologic Diseases (19) · Urogenital Diseases (19) · Breast Diseases (18) · Neoplasms, Glandular and Epithelial (18)
Carboplatin (11) · Cisplatin (6) · Paclitaxel (6) · Trastuzumab (6) · 130-nm albumin-bound paclitaxel (5) · Cyclophosphamide (5) · Doxorubicin (4) · Gemcitabine (4) · pembrolizumab (4) · Bortezomib (3) · Cytarabine (3) · Docetaxel (3) · Drug Therapy (3) · Fluorouracil (3) · Oxaliplatin (3)
National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (5) · Assistance Publique - Hôpitaux de Paris (3) · Henan Cancer Hospital (3) · Peking University People's Hospital (3) · Tang-Du Hospital (3) · AGC Biologics S.p.A. (2) · Fudan University (2) · National Taiwan University Hospital (2) · University of Minnesota (2) · Virginia Commonwealth University (2) · Weill Medical College of Cornell University (2) · Yale University (2) · AC Camargo Cancer Center (1) · ARCAGY/ GINECO GROUP (1)
United States (44) · China (27) · France (10) · Italy (8) · Germany (7) · United Kingdom (5) · Spain (4) · Canada (3) · Hungary (3) · Belgium (2) · Israel (2) · Mexico (2) · Poland (2) · Puerto Rico (2) · Taiwan (2)
Zhenzhen Liu (3) · Antonio Lambiase, MD (2) · Xiaohui Zhang, MD (2) · Agop Y. Bedikian, MD, BS (1) · Alberto Zambelli, MD (1) · Amado Zurita, MD (1) · Amir Fathi, MD (1) · Andrea Botticelli, MD (1) · Andreas Hartmann, MD (1) · Andrew Poklepovic, MD (1) · Angel Arnaout, MD (1) · Ann Van de Velde, MD, PhD (1) · Arif Awan, MD (1) · Armando Giuliano, MD, FACS, FRCSEd (1) · Asit Paul, MD (1)
PMID 19008157, PMID 19299237, PMID 19692142, PMID 20211870, PMID 20844049, PMID 21796368, PMID 21865400, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23592699, PMID 24529560, PMID 25092775, PMID 25261096, PMID 26083430, PMID 26285768, PMID 26571268, PMID 26812052, PMID 27403743, PMID 27406346, PMID 27406347, PMID 27776843, PMID 27872127, PMID 28317872, PMID 28851423, PMID 28869790, PMID 29298660, PMID 29386195, PMID 30642373, PMID 30763338, PMID 30982686, PMID 31639132, PMID 32031889, PMID 32053137, PMID 32101663, PMID 32120420, PMID 32393788, PMID 32450725, PMID 32476546, PMID 32669709, PMID 32701140, PMID 32848145, PMID 32966830, PMID 33181091, PMID 33278935, PMID 33373868, PMID 33394722, PMID 33741467, PMID 34482636, PMID 34529000
2016 (2), 2015 (1), 2018 (1), 2023 (1), 2025 (1), P30CA012197 (1), P30CA016672 (1), P30CA060553 (1), T32CA233414 (1)